Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593256 | 0.91 | KCNH2 (0.43) | CYP2C9KCNH2SCN1ASCN4ASCN5A | |
| SCHEMBL18581189 | 0.89 | CYP2C9 (0.53) | CYP2C9HDAC1HDAC6SMN1; SMN2ROCK2 | |
| SCHEMBL18581428 | 0.89 | HDAC6 (0.53) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| SCHEMBL28629242 | 0.89 | CYP2C9 (0.50) | CYP2C9HDAC1HDAC6SMN1; SMN2ROCK2 | |
| SCHEMBL18581215 | 0.85 | CYP2C9 (0.54) | CYP2C9HDAC1HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL28624625 | 0.80 | GAA (0.47) | CYP2C9HDAC1HDAC6SMN1; SMN2ROCK2 | |
| SCHEMBL18581835 | 0.79 | HDAC6 (0.58) | HDAC1HDAC6SMN1; SMN2TSHRRAB9A | |
| SCHEMBL17957654 | 0.76 | ROCK2 (0.53) | CYP2C9KCNH2SCN1ASCN4ASCN5A | |
| SCHEMBL6915258 | 0.76 | HDAC1 (0.45) | CYP2C9KCNH2HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL23769113 | 0.76 | ROCK2 (0.50) | CYP2C9SCN9AHDAC1HDAC6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CYP2C9 874/4885MRGPRX4 1870/4885KCNH2 2468/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CYP2C9 874/4885MRGPRX4 1870/4885KCNH2 2468/4885 |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | CYP2C9 874/4885MRGPRX4 1870/4885KCNH2 2468/4885 |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CYP2C9 874/4885MRGPRX4 1870/4885KCNH2 2468/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | CYP2C9 2641/4885MRGPRX4 2728/4885KCNH2 1787/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | CYP2C9 874/4885MRGPRX4 1870/4885KCNH2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.